Autopsy report · NCT03111901

Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer

“funding was withdrawn”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

William Grosh, MD

Sponsor type

University, hospital or other

Conditions

Carcinoma, Renal Cell; Melanoma

Interventions

Pembrolizumab; Interleukin-2

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Walnuts and Glucose Variability
  “Funding withdrawn” (96% match in meaning)
• Hydroxychloroquine Efficacy in Chronic Urticaria
  “withdrawn, not funded” (90% match in meaning)
• The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical PKU
  “Withdrawn due to no funding” (88% match in meaning)
• Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation
  “Withdrawal of funding” (85% match in meaning)
• Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study
  “Funding for study was withdrawn” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.